Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads heart traces to find silent liver danger

NCT ID NCT05782283

Diagnosis Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether an artificial intelligence (AI) tool, called ACE 2.0, can detect undiagnosed liver cirrhosis by analyzing a routine electrocardiogram (ECG). Researchers at Mayo Clinic enrolled 279 primary care clinicians and their adult patients. The AI flagged ECGs that might indicate advanced liver disease, and doctors were alerted. The goal was to see if this approach leads to more early diagnoses compared to usual care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-powered ECG tool (ACE 2.0)
What this could lead to
If it works, this could give doctors a simple, cheap way to catch serious liver disease early, before it causes major damage.
What could go wrong
This was a small, early study (279 people) and only looked at detection, not treatment. The AI might miss cases or cause unnecessary worry.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

279 people

The number who actually took part.

Started

Apr 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Criteria: Inclusion Criteria: * Primary care clinicians (physicians, nurse practitioners, and physician assistants). * Part of a team that cares for adult patients (≥18 years). * Have the ability to order ECG. * Consent will be obtained from primary care clinicians. * Patients' data will be collected from electronic medical records (EMR). * Adult patients (≥ 18 years) undergoing an ECG for any indication over a period of 6 months will be included. Exclusion Criteria: * Patients with known cirrhosis based on noninvasive fibrosis assessment tests, liver biopsy or complications of decompensated disease, or with a documented history of cirrhosis identified by clinical notes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced liver fibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis fibrotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhosis

Contacts and locations

Locations

  • Mayo Clinic Minnesota

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.